Founded by University of Washington faculty, Proprio has raised series A funding to commercialise its multi-camera surgical imaging system.

Backed by Intel and HTC as of its launch early last year, Proprio has now raised a total of $30m to commercialise its multi-camera surgical imaging system.

Grand Decade and existing investor Boehringer Ingelheim Venture Fund helped supply $38.2m for the mRNA immunotherapy developer and Vrije Universiteit Brussel spinout.

Chalmers Ventures portfolio company Biofrigas has set out plans for a $1.7m IPO but has already issued around $1.2m to existing connections.

The demographic phenomenon of ageing populations will present challenges to both developed and developing nations. Along with the challenges come opportunities, however, and corporate venture capitalists may be a particularly well-positioned group to help with them, as it is the connecting tissue between the world of incumbent corporate industry leaders and the space of disruptive innovation.

The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Novartis and Eli Lilly are set to score exits from the cancer and blood disease drug developer in an initial public offering set to raise up to $212m.

4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.

Pfizer Ventures and Chiesi Ventures returned to back inherited disease therapy developer 4D Molecular Therapeutics, which filed to go public in September.